Search All UT System Experts

Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors

Vandana G. Abramson, Jeffrey G. Supko, Tarah Ballinger, James M. Cleary, John F. Hilton, Sara M. Tolaney, Nicole G. Chau, Daniel C. Cho, Joseph Pearlberg, Joanne Lager, Geoffrey I. Shapiro, Carlos L. Arteaga

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences